1月17日,先声药业官方公众号发布与费米子科技合作开发国内首个SSTR4靶点镇痛药物消息。披露公司和广州费米子科技有限责任公司共同宣布,双方已就一款靶向SSTR4的临床阶段镇痛候选创新药FZ002-037达成合作。FZ002-037项目是由费米子科技开发的高选择性口服小分子SSTR4激动剂,临床前研究显示,该靶点主要作用于外周镇痛,无中枢副作用和成瘾性等问题,有望为有长期用药需求的患者提供新选择。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.